Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company TissueGene has initiated a phase I clinical trial evaluating a single dose of its investigational compaound TG-C for the treatment of degenerative joint diseases.
Subscribe to our email newsletter
This clinical trial is designed to assess the safety of TG-C in patients who have opted for total knee arthroplasty.
TissueGene has developed TG-C to regenerate cartilage in patients suffering from degenerative arthritis and more specifically for indications such as osteoarthritis of the knee. As an alternative to other methods of cartilage repair, TG-C will involve minimally invasive injections versus a surgical approach. Other techniques currently involve multiple and often invasive surgical procedures and have mixed results.
“We are pleased with the approval to start our phase I program with TG-C and feel that our drug candidate has the potential to be not first-in-class, but also best-in-class,” stated Dr K.H. Lee, president, founder and CEO of TissueGene.